Watson Oxytrol Using "Direct-To-Patient" Promotion In Physician Waiting Room
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson expects products from GlaxoSmithKline and Novartis to grow the overactive bladder market in 2005. Before their entry, Watson will have the opportunity to bulk up its sales force through acquisition of sales reps from Ventiv.